Patrick Aebischer

EPFL SV SV-DEC PH-SV
SV 3807 (Bâtiment SV)
Station 19
1015 Lausanne

Patrick Aebischer a achevé une formation en Médecine (1980) et en Neurosciences (1983) aux Universités de Genève et de Fribourg en Suisse. De 1984 à 1992, Patrick Aebischer a travaillé à Brown University (USA) au sein du Département des Neurosciences et au Département des Biomatériaux et des Organes Artificiels en tant que Professeur assistant, puis Professeur associé. En 1992, Patrick Aebischer a été nommé Professeur de la Division Autonome de Recherche Chirurgicale et du Centre de Thérapie Génique (DARC) au Centre Hospitalier Universitaire Vaudois (CHUV) à Lausanne. En 1999, Le Conseil Fédéral a nommé Patrick Aebischer en tant que Président de l'Ecole Polytechnique Fédérale de Lausanne (EPFL). Il a pris ses fonctions à la Présidence de l'EPFL en mars 2000, position qu'il a occupée jusqu'au 31 décembre 2016. Patrick Aebischer est membre de maintes sociétés professionnelles, tant en Europe qu'aux Etats-Unis. Patrick Aebischer a fondé trois start-up de biotechnologies. Il siège au conseil d'administration de Lonza, de Logitech et de Nestlé. Il préside également l'advisory board du Novartis Venture Fund. Patrick Aebischer est membre du conseil de fondation du Festival de Jazz de Montreux, du Festival de Verbier et de la Fondation Jacobs. Les recherches qu'il poursuit actuellement dans son laboratoire se concentrent sur le développement d'approches de thérapie cellulaire et de transfert génique pour le traitement des maladies neurodégénératives.

A subcutaneous cellular implant for passive immunization against amyloid-beta reduces brain amyloid and tau pathologies

A. LathuiliereV. LaversenneA. AstolfoE. KopetzkiH. Jacobsen  et al.

Brain. 2016. DOI : 10.1093/brain/aww036.

Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents

D. RyuL. MouchiroudP. A. AndreuxE. KatsyubaN. Moullan  et al.

Nat Med. 2016. DOI : 10.1038/nm.4132.

In Vivo Evidence for a Lactate Gradient from Astrocytes to Neurons

P. MachlerM. T. WyssM. ElsayedJ. StobartR. Gutierrez  et al.

Cell Metabolism. 2016. DOI : 10.1016/j.cmet.2015.10.010.

Alpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease

W. BobelaP. AebischerB. L. Schneider

Biomolecules. 2015. DOI : 10.3390/biom5042675.

SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice

E. DirrenJ. AebischerC. RochatC. TowneB. L. Schneider  et al.

Annals Of Clinical And Translational Neurology. 2015. DOI : 10.1002/acn3.162.

Tmc gene therapy restores auditory function in deaf mice

C. AskewC. RochatB. PanY. AsaiH. Ahmed  et al.

Science Translational Medicine. 2015. DOI : 10.1126/scitranslmed.aab1996.

Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology

S. YangM. CacquevelL. M. SaksidaT. J. BusseyB. L. Schneider  et al.

Experimental neurology. 2015. DOI : 10.1016/j.expneurol.2014.11.013.

Channel-Mediated Lactate Release by K+-Stimulated Astrocytes

T. Sotelo-HitschfeldM. I. NiemeyerP. MaechlerI. RuminotR. Lerchundi  et al.

Journal Of Neuroscience. 2015. DOI : 10.1523/Jneurosci.5036-14.2015.

Intracerebroventricular Injection of Adeno-Associated Virus 6 and 9 Vectors for Cell Type-Specific Transgene Expression in the Spinal Cord

E. DirrenC. L. TowneV. SetolaD. E. J. RedmondB. L. Schneider  et al.

Human Gene Therapy. 2014. DOI : 10.1089/hum.2013.021.

A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity

J. DusonchetH. LiM. GuillilyM. LiuK. Stafa  et al.

Human Molecular Genetics. 2014. DOI : 10.1093/hmg/ddu202.

Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation

A. LathuiliereB. BohrmannE. KopetzkiC. SchweitzerH. Jacobsen  et al.

Biomaterials. 2014. DOI : 10.1016/j.biomaterials.2013.10.026.

Direct and Retrograde Transduction of Nigral Neurons with AAV6, 8, and 9 and Intraneuronal Persistence of Viral Particles

K. LoewP. AebischerB. L. Schneider

Human Gene Therapy. 2013. DOI : 10.1089/hum.2012.174.

Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo

A. OueslatiB. L. SchneiderP. AebischerH. A. Lashuel

Proceedings of the National Academy of Sciences of the United States of America. 2013. DOI : 10.1073/pnas.1309991110.

Astrocyte–neuron co-culture on microchips based on the model of SOD mutation to mimic ALS

A. KunzeS. LengacherE. DirrenP. AebischerP. J. Magistretti  et al.

Integrative Biology. 2013. DOI : 10.1039/c3ib40022k.

Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model

E. DassieM. R. AndrewsJ.-C. BensadounM. CacquevelB. L. Schneider  et al.

Neurobiology Of Aging. 2013. DOI : 10.1016/j.neurobiolaging.2012.11.011.

Philanthropy: The price of charity

P. Aebischer

Nature. 2012. DOI : 10.1038/481260a.

Use of viral vectors to create animal models for Parkinson's disease

K. LoewP. Aebischer

Neurobiology Of Disease. 2012. DOI : 10.1016/j.nbd.2011.12.038.

Parkinson's Disease: Gene Therapies

P. G. CouneB. L. SchneiderP. Aebischer

Cold Spring Harbor Perspectives In Medicine. 2012. DOI : 10.1101/cshperspect.a009431.

Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity

M. N. GauglerO. GencW. BobelaS. MohannaM. T. Ardah  et al.

Acta Neuropathologica. 2012. DOI : 10.1007/s00401-012-0963-y.

Mimicking Phosphorylation at Serine 87 Inhibits the Aggregation of Human α-Synuclein and Protects against Its Toxicity in a Rat Model of Parkinson's Disease

A. OueslatiK. E. PaleologouB. L. SchneiderP. AebischerH. A. Lashuel

The Journal of neuroscience : the official journal of the Society for Neuroscience. 2012. DOI : 10.1523/JNEUROSCI.3784-11.2012.

Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function

C. CironS. LengacherJ. DusonchetP. AebischerB. Schneider

Human Molecular Genetics. 2012. DOI : 10.1093/hmg/ddr618.

Rab1A Over-Expression Prevents Golgi Apparatus Fragmentation and Partially Corrects Motor Deficits in an Alpha-Synuclein Based Rat Model of Parkinson’s Disease

P. G. CouneJ.-C. BensadounP. AebischerB. Schneider

Journal of Parkinson's Disease. 2011. DOI : 10.3233/JPD-2011-11058.

Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool

O. Marroquin BelaunzaranM. I. CorderoV. SetolaS. BianchiC. Galli  et al.

Plos One. 2011. DOI : 10.1371/journal.pone.0018268.

Neuroprotection by Gene Therapy Targeting Mutant SOD1 in Individual Pools of Motor Neurons Does not Translate Into Therapeutic Benefit in fALS Mice

C. TowneV. SetolaB. L. SchneiderP. Aebischer

Molecular therapy : the journal of the American Society of Gene Therapy. 2010. DOI : 10.1038/mt.2010.260.

Neurodegenerative Disorders: Gene Therapy on Clinical Trial

P. Aebischer

Frontiers in Neuroscience. 2010.

Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model

R. MastroeniJ.-C. BensadounD. CharvinP. AebischerA. Pujol  et al.

Annals of Neurology. 2009. DOI : 10.1002/ana.21677.

A versatile tool for conditional gene expression and knockdown

J. SzulcM. WiznerowiczM.-O. SauvainD. TronoP. Aebischer

Nature Methods. 2006. DOI : 10.1038/nmeth846.